INmune Bio Management
Management criteria checks 2/4
INmune Bio's CEO is RJ Tesi, appointed in Sep 2015, has a tenure of 9.17 years. total yearly compensation is $1.69M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 7.01% of the company’s shares, worth $7.58M. The average tenure of the management team and the board of directors is 9.1 years and 7.9 years respectively.
Key information
RJ Tesi
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.5% |
| CEO tenure | 9.2yrs |
| CEO ownership | 7.0% |
| Management average tenure | 9.1yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Nov 03
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
Sep 30It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$2m | US$501k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$1m | US$455k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$33m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$3m | US$455k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$300k | US$300k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$1m | US$248k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$3m | US$120k | -US$12m |
Compensation vs Market: RJ's total compensation ($USD1.69M) is above average for companies of similar size in the US market ($USD646.00K).
Compensation vs Earnings: RJ's compensation has increased whilst the company is unprofitable.
CEO
RJ Tesi (68 yo)
9.2yrs
Tenure
US$1,694,818
Compensation
Dr. Raymond Joseph Tesi, MD, also known as RJ, serves as Director at Bexion Pharmaceuticals, Inc. Dr. Tesi is the Co-Founder of INmuneBio Inc. and has been its Chief Medical Officer and Chairman and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.2yrs | US$1.69m | 7.01% $ 7.6m | |
| CFO, Treasurer & Secretary | 9.2yrs | US$1.59m | 5.8% $ 6.3m | |
| Chief Scientific Officer & Chief Manufacturing Officer | 9.1yrs | US$150.24k | 6.81% $ 7.4m | |
| General Counsel | 5.8yrs | no data | no data |
9.1yrs
Average Tenure
61yo
Average Age
Experienced Management: INMB's management team is seasoned and experienced (9.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.2yrs | US$1.69m | 7.01% $ 7.6m | |
| Independent Director | 5yrs | US$301.66k | no data | |
| Independent Director | 6.7yrs | US$301.66k | 0.32% $ 349.4k | |
| Independent Director | 8.2yrs | US$301.66k | 0.080% $ 86.8k | |
| Independent Director | 7.9yrs | US$301.26k | 0.37% $ 401.1k |
7.9yrs
Average Tenure
66yo
Average Age
Experienced Board: INMB's board of directors are considered experienced (7.9 years average tenure).